Inclusion Criteria
 Participant is willing and able to give informed consent for participation in the study;
 Participant is willing to comply with all trial procedures;
 Onset of symptoms of possible COVID-19 in the community (continuous cough and/or high temperature) within 7 days of inclusion;
 Patients aged ≥50-64 years with any of the following listed comorbidities:
 Known weakened immune system due to a serious illness or medication (e.g. chemotherapy);
 Known heart disease and/ or hypertension;
 Known asthma or lung disease;
 Known diabetes not treated with insulin;
 Known mild hepatic impairment;
 Known stroke or neurological problem;
OR
 Patients aged ≥65 with or without comorbidity

Exclusion Criteria
 Pregnancy;
 Breastfeeding;
 Known severe hepatic impairment;
 Known severe renal impairment;
 Known porphyria;
 Type 1 diabetes or insulin dependent Type 2 Diabetes mellitus ;
 Known G6PD deficiency;
 Known myasthenia gravis;
 Known severe psoriasis;
 Known severe neurological disorders (especially those with a history of epilepsy—may lower seizure threshold);
 Previous adverse reaction to, or currently taking, hydroxychloroquine;
 Patients taking the following drugs: penicillamine, amiodarone, ciclosporin, chloroquine
 Known retinal disease;
 Judgement of the recruiting clinician deems ineligible.

PARTICIPANTS INFORMATION LEAFLET

Please contact Nicola, the Practice Manager, if you believe you are eligible for this study